Suzhou Zelgen Biopharmaceuticals Co.,Ltd. (SHA:688266)

SHA:688266 Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	-	2,110	797.05	1,137	1,150
Trading Asset Securities	-	137.02	248.93	65.26	449.85
Cash & Short-Term Investments	2,204	2,247	1,046	1,202	1,600
Cash Growth	-1.92%	114.79%	-12.97%	-24.86%	2093.61%
Accounts Receivable	-	101.14	88.99	62.37	-
Other Receivables	-	10.89	12.51	12.45	2.62
Receivables	-	112.03	101.5	74.82	2.62
Inventory	-	110.85	98.98	51.91	23.14
Prepaid Expenses	-	-	-	-	0.39
Other Current Assets	-	50.79	45.3	77.33	43.83
Total Current Assets	-	2,520	1,292	1,406	1,670
Property, Plant & Equipment	-	271.21	247.09	188.91	91.03
Long-Term Investments	-	5.99	10	10	10
Other Intangible Assets	-	69.27	91.03	116.29	129.51
Long-Term Deferred Charges	-	16.39	20.96	13.03	4.35
Other Long-Term Assets	-	4.02	7.48	11.78	65.82
Total Assets	-	2,887	1,668	1,746	1,970
Accounts Payable	-	137.73	151.72	118.19	64.96
Accrued Expenses	-	74.96	67.5	48.22	30.92
Short-Term Debt	-	795.16	390.79	131.81	17.67
Current Portion of Long-Term Debt	-	50.56	50.04	30.03	-
Current Portion of Leases	-	13.17	13.69	13.55	-
Current Income Taxes Payable	-	20.64	20.29	18.58	16.94
Current Unearned Revenue	-	-	0.28	0.36	-
Other Current Liabilities	-	42.95	34.88	20.16	10.38
Total Current Liabilities	-	1,135	729.19	380.89	140.88
Long-Term Debt	-	-	50.09	-	30.03
Long-Term Leases	-	29.46	43.18	48.18	4.32
Long-Term Unearned Revenue	-	11.55	45.04	48.05	83.66
Long-Term Deferred Tax Liabilities	-	9.58	13.32	15.77	19.81
Other Long-Term Liabilities	-	56.6	-	-	-
Total Liabilities	-	1,242	880.82	492.88	278.69
Common Stock	-	264.71	240	240	240
Additional Paid-In Capital	-	3,353	2,222	2,205	2,174
Retained Earnings	-	-1,979	-1,700	-1,243	-791.56
Comprehensive Income & Other	-	-5.95	-2.84	-6.32	-5.04
Total Common Equity	1,303	1,633	759.12	1,196	1,618
Minority Interest	-	11.98	28.37	56.76	73.86
Shareholders' Equity	1,303	1,645	787.49	1,253	1,692
Total Liabilities & Equity	-	2,887	1,668	1,746	1,970
Total Debt	923.07	888.35	547.8	223.57	52.02
Net Cash (Debt)	1,281	1,358	498.18	978.32	1,548
Net Cash Growth	-5.72%	172.65%	-49.08%	-36.78%	19021.89%
Net Cash Per Share	4.79	5.31	2.08	4.08	6.59
Filing Date Shares Outstanding	274.55	264.71	264.49	240	240
Total Common Shares Outstanding	264.71	264.71	240	240	240
Working Capital	-	1,385	562.57	1,025	1,529
Book Value Per Share	4.92	6.17	3.16	4.98	6.74
Tangible Book Value	1,249	1,564	668.09	1,080	1,488
Tangible Book Value Per Share	4.72	5.91	2.78	4.50	6.20
Buildings	-	41.93	41.93	41.21	-
Machinery	-	125.42	121.74	96.02	-
Construction In Progress	-	135.83	86.67	27.25	-

Source: S&P Capital IQ. Standard template. Financial Sources.